Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177


Mutant p53 exerts oncogenic effects through microRNAs and their target gene networks.

Li XL, Jones MF, Subramanian M, Lal A.

FEBS Lett. 2014 Aug 19;588(16):2610-5. doi: 10.1016/j.febslet.2014.03.054. Epub 2014 Apr 12. Review.


Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression.

Wang W, Cheng B, Miao L, Mei Y, Wu M.

Cell Death Dis. 2013 Apr 4;4:e574. doi: 10.1038/cddis.2013.97.


Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.

Neilsen PM, Noll JE, Mattiske S, Bracken CP, Gregory PA, Schulz RB, Lim SP, Kumar R, Suetani RJ, Goodall GJ, Callen DF.

Oncogene. 2013 Jun 13;32(24):2992-3000. doi: 10.1038/onc.2012.305. Epub 2012 Jul 16.


A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis.

Subramanian M, Francis P, Bilke S, Li XL, Hara T, Lu X, Jones MF, Walker RL, Zhu Y, Pineda M, Lee C, Varanasi L, Yang Y, Martinez LA, Luo J, Ambs S, Sharma S, Wakefield LM, Meltzer PS, Lal A.

Oncogene. 2015 Feb 26;34(9):1094-104. doi: 10.1038/onc.2014.46. Epub 2014 Mar 24.


CD95 is part of a let-7/p53/miR-34 regulatory network.

Hau A, Ceppi P, Peter ME.

PLoS One. 2012;7(11):e49636. doi: 10.1371/journal.pone.0049636. Epub 2012 Nov 14.


p53 enters the microRNA world.

Hermeking H.

Cancer Cell. 2007 Nov;12(5):414-8. Review.


Conserved regulation of p53 network dosage by microRNA-125b occurs through evolving miRNA-target gene pairs.

Le MT, Shyh-Chang N, Khaw SL, Chin L, Teh C, Tay J, O'Day E, Korzh V, Yang H, Lal A, Lieberman J, Lodish HF, Lim B.

PLoS Genet. 2011 Sep;7(9):e1002242. doi: 10.1371/journal.pgen.1002242. Epub 2011 Sep 15.


The p53/microRNA network in cancer: experimental and bioinformatics approaches.

H√ľnten S, Siemens H, Kaller M, Hermeking H.

Adv Exp Med Biol. 2013;774:77-101. doi: 10.1007/978-94-007-5590-1_5. Review.


MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth.

Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY.

Cancer Res. 2007 Sep 15;67(18):8433-8. Epub 2007 Sep 6.


P53/microRNA-34-induced metabolic regulation: new opportunities in anticancer therapy.

Zhang DG, Zheng JN, Pei DS.

Mol Cancer. 2014 May 21;13:115. doi: 10.1186/1476-4598-13-115. Review.


miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.

Kasinski AL, Slack FJ.

Cancer Res. 2012 Nov 1;72(21):5576-87. doi: 10.1158/0008-5472.CAN-12-2001. Epub 2012 Sep 10.


MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251.

Luan S, Sun L, Huang F.

Arch Med Res. 2010 Feb;41(2):67-74. doi: 10.1016/j.arcmed.2010.02.007.


[miR-34s--a tumor suppression protein p53 highly related microRNA].

Lou WJ, Chen Q, Liu L, Qian C.

Yi Chuan. 2010 May;32(5):423-30. Review. Chinese.


MicroRNA Control of p53.

Liu J, Zhang C, Zhao Y, Feng Z.

J Cell Biochem. 2017 Jan;118(1):7-14. doi: 10.1002/jcb.25609. Epub 2016 Jun 3. Review.


p53 represses c-Myc through induction of the tumor suppressor miR-145.

Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3207-12. doi: 10.1073/pnas.0808042106. Epub 2009 Feb 6.


Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215.

Georges SA, Biery MC, Kim SY, Schelter JM, Guo J, Chang AN, Jackson AL, Carleton MO, Linsley PS, Cleary MA, Chau BN.

Cancer Res. 2008 Dec 15;68(24):10105-12. doi: 10.1158/0008-5472.CAN-08-1846.


MicroRNAs, wild-type and mutant p53: more questions than answers.

Jones M, Lal A.

RNA Biol. 2012 Jun;9(6):781-91. doi: 10.4161/rna.20146. Epub 2012 Jun 1. Review.


miR-150, p53 protein and relevant miRNAs consist of a regulatory network in NSCLC tumorigenesis.

Wang DT, Ma ZL, Li YL, Wang YQ, Zhao BT, Wei JL, Qi X, Zhao XT, Jin YX.

Oncol Rep. 2013 Jul;30(1):492-8. doi: 10.3892/or.2013.2453. Epub 2013 May 13.


Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.

Masciarelli S, Fontemaggi G, Di Agostino S, Donzelli S, Carcarino E, Strano S, Blandino G.

Oncogene. 2014 Mar 20;33(12):1601-8. doi: 10.1038/onc.2013.106. Epub 2013 Apr 15.


Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway.

Ma X, Choudhury SN, Hua X, Dai Z, Li Y.

Carcinogenesis. 2013 Jun;34(6):1216-23. doi: 10.1093/carcin/bgt044. Epub 2013 Feb 5.

Supplemental Content

Support Center